Company Curis, Inc. Nasdaq

Equities

US2312691015

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.

USD in Million	2022	Weight	2023	Weight	Delta
Discovery and Development of Innovative Drug 100.0 %	10	100.0 %	10	100.0 %	-1.37%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	10	100.0 %	10	100.0 %	-1.37%

Managers	Title	Age	Since
James Dentzer CEO	Chief Executive Officer	57	28/03/16
Diantha Duvall DFI	Director of Finance/CFO	52	25/07/22
Kimberly Steinmann CTO	Chief Tech/Sci/R&D Officer	-	02/01/22
Reinhard von Roemeling CTO	Chief Tech/Sci/R&D Officer	-	12/08/19
Robert Martell CTO	Chief Tech/Sci/R&D Officer	61	31/08/11
Mark W. Noel CTO	Chief Tech/Sci/R&D Officer	65	28/02/01
Rachel Blasbalg HRO	Human Resources Officer	-	31/12/03
Dora Ferrari PRN	Corporate Officer/Principal	-	02/01/21
Nancy Soohoo LAW	General Counsel	-	31/12/02
Jonathan Zung PRN	Corporate Officer/Principal	59	30/04/23

Members of the board	Title	Age	Since
Kenneth Kaitin BRD	Director/Board Member	71	31/10/03
Martyn Greenacre CHM	Chairman	82	13/02/00
James Dentzer CEO	Chief Executive Officer	57	28/03/16
Marc Rubin BRD	Director/Board Member	69	02/06/10
Robert Martell CTO	Chief Tech/Sci/R&D Officer	61	31/08/11
Anne Borgman BRD	Director/Board Member	56	30/09/22
John Hohneker BRD	Director/Board Member	64	01/12/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	5,894,085	5,883,204 ( 99.82 %)	0	99.82 %

Name	Equities	%	Valuation
Maverick Capital Ltd. 9.879 %	582,273	9.879 %	8 M $
M28 Capital Management LP 7.159 %	421,951	7.159 %	6 M $
Kingdon Capital Management LLC 5.866 %	345,730	5.866 %	5 M $
Kingdon Capital Management LLC 4.821 %	284,150	4.821 %	4 M $
Vanguard Global Advisers LLC 3.708 %	218,573	3.708 %	3 M $
Citigroup Global Markets, Inc. (Investment Management) 1.559 %	91,872	1.559 %	1 M $
Renaissance Technologies LLC 1.553 %	91,563	1.553 %	1 M $
Geode Capital Management LLC 1.057 %	62,299	1.057 %	904 581 $
BlackRock Institutional Trust Co. NA 0.9074 %	53,484	0.9074 %	776 588 $
Focused Wealth Management, Inc. 0.5626 %	33,158	0.5626 %	481 454 $

Curis, Inc.

Building C 128 Spring Street

02421, Lexington

+617 503 6500

http://www.curis.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+26.37%	48.16B
IQVIA HOLDINGS INC.	-1.01%	41.73B
LONZA GROUP AG	+43.40%	41.03B
CELLTRION, INC.	-5.31%	28.77B
ICON PUBLIC LIMITED COMPANY	+9.34%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	18.96B
BIO-TECHNE CORPORATION	+6.23%	12.92B
MEDPACE HOLDINGS, INC.	+26.99%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.77B

Other Biotechnology & Medical Research